Headline News:
Data Provide Evidence that Genous Could Be Treatment for Patients Not Suitable for Long Term DAPT
March 12th, 2010
Al Novak has over 27 years of leadership experience in the medical technology industry having served as chief executive officer of Novoste Corporation (a NASDAQ listed company) and Biosense, Inc. (acquired by Johnson & Johnson in 1998). Al has over 13 years with Cordis Corporation (listed on NASDAQ until its acquisition by Johnson & Johnson in 1996) in various marketing, financial, and business development positions, including vice president and chief financial officer. Mr. Novak was a founder of Syntheon LLC and currently serves on the board of directors of Cyberonics Inc. (a NASDAQ listed company).